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Abstract
High-resolution computed tomography (HRCT) imaging has a central role in the diagnosis of interstitial lung
diseases, particularly in the evaluation of patients with suspected idiopathic pulmonary fibrosis (IPF). In
approximately half of cases, HRCT scans are sufficient to allow a confident IPF diagnosis. Advances in HRCT
scanning and interpretation have facilitated improved accuracy for use in diagnosing IPF, eliminating the need for
a surgical biopsy in many patients. HRCT may also have a role to play in predicting the prognosis of the disease;.
The role of routine follow-up with HRCT to monitor patients with IPF remains unclear due to lack of sufficient
evidence, although, sometimes follow-up HRCT might be necessary to rule out progressive disease in patients with
undetermined diagnosis. Advances in the field of HRCT imaging are discussed, along with insights into the clinical
utility of this procedure in the diagnosis and management of IPF.
Introduction
High-resolution computed tomography (HRCT) may
substantially narrow the differential diagnosis for most
cases with clinically suspected interstitial lung disease
(ILD). Sometimes, HRCT may also provide a confident
diagnosis without the need of the surgical biopsy.
Furthermore, HRCT can quantify the extent of lung
abnormalities and be used to make up composite indexes
that better estimate disease severity and prognosis [1-3].
Indeed, HRCT is an essential tool for the evaluation of
patients with suspected idiopathic pulmonary fibrosis
(IPF) and has been increasingly used in several drug trials
as a surrogate index for assessing treatment response
[4-7]. The following highlights summarize the key techni-
cal requirements for improving HRCT imaging of patients
with IPF, the HRCT role in IPF diagnosis and follow-up.
Key technical requirements for best practice HRCT
The key technical requirements for ‘best practice’ HRCT
are volumetric acquisition and thin-section reconstruction.
Volumetric HRCT acquisition is now generally preferred
to standard noncontiguous HRCT imaging (eg, 1mm
scans with 10mm interval) because it improves both the
identification of ancillary findings (e.g. lung nodules), and
the characterization of patchy ILD [8]. Importantly, volu-
metric HRCT acquisition allows for better differentiation
between honeycombing and traction bronchiectasis which
may be proved crucial to diagnose or rule out IPF. Only
volumetric imaging data provides multiplanar reforma-
tions (coronal and sagittal) of the entire lung improving
the evaluation of abnormalities distribution and the extent
of disease [9]. However, volumetric HRCT acquisition
should only be performed if state-of-the-art multidetector-
rows CT scanners (with at least 16 detector-rows) are
available as the scanning time of early scanners (eg 4-6
detector-rows) is too long, with most patients unable to
hold their breath long enough for a complete lung scan. .
The major drawback of the volumetric technique is the
high radiation dose exposure. Such a concern should be
taken into account particularly when examining young
patients with suspected ILD for whom standard noncon-
tiguous HRCT should be considered as they deliver about
one-fourth of the dose of standard volumetric HRCT [10].
Nevertheless, it is important to realize that reducing the
tube current up to 20-30 mAs for volumetric HRCT scan-
ning does not significantly impair the visual assessment of
the lung parenchyma [11-14]. The increasing development
of tools for reducing radiation exposure (e.g. automatic
exposure control, iterative reconstruction) is reasonable
assuming that diagnostic performance is not compromised
[10,15].Scienze Radiologiche, Padiglione Barbieri, Azienda Ospealiero-Universitaria di
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Expiratory CT scanning might refine the differential
diagnosis of fibrotic lung diseases by disclosing coexisting
air trapping [16]. However it has yet to be proven
whether or not the regular use of expiratory CT scanning
provides any additional benefit in terms of diagnostic
accuracy at the cost of increased radiation exposure.
HRCT scans are usually obtained with the patient in
supine position. However, when limited (not extensive)
ILD is suspected (by the clinical auscultation and/or the
evaluation of the chest radiograph) prone imaging could
be of use. Thus, the frequent finding of an amorphous
increase in attenuation of the dependent lung (in the
supine position, the postero-basal segments of the lower
lobes) may mimic subtle interstitial abnormalities. How-
ever, this can be generally readily recognized as a normal
finding if there are CT sections obtained in the prone
position that confirm its reversibility [17].
Definitive pattern of usual interstitial pneumonia
(UIP) pattern at HRCT
Familiarity with the typical appearances of UIP on HRCT
is important, as in the appropriate clinical setting, it is
often sufficient for establishing a confident diagnosis of
IPF without the need for surgical biopsy [6].
The characteristic HRCT features of UIP are a reticular
pattern with honeycombing, often associated with traction
bronchiectasis; ground glass may be present, but is less
extensive than reticular abnormality. Such abnormalities
are characteristically basal and peripheral, though often
patchy (Figure 1) [4].
Subpleural, basal honeycombing is indeed the most
important, specific feature of the UIP pattern. On HRCT,
honeycombing consists of clustered cystic airspaces, typi-
cally of comparable diameters of the order of 3–10 mm,
though these may occasionally be as large as 2.5 cm. Hon-
eycombing is characterized by well-defined walls [18]. In
some cases of UIP with concurrent emphysema, emphyse-
matous areas surrounded by ground-glass and/or reticular
opacity may mimic honeycombing. In a study by Akira et
al, it was shown that emphysematous changes complicated
the interpretation of the CT findings thus leading to incor-
rect differential diagnosis between UIP and nonspecific
interstitial pneumonia (NSIP) in more than half of the
cases [19].
Although it’s still not clear if IPF with coexisting emphy-
sema represents a distinct clinical phenotype (combined
pulmonary fibrosis and emphysema) or whether emphy-
sema in these cases is simply a comorbidity, identifying
coexisting emphysema may be important to better inter-
pret pulmonary function test results [20-22]. Furthermore,
it has been suggested that patients with IPF combined
with emphysema are more likely develop pulmonary
Figure 1 Definite UIP pattern. Transverse high-resolution computed tomography (HRCT) image shows subpleural basal honeycombing (more
evident in the left lung) with traction bronchiectasis, reticular and ground-glass opacities.
Sverzellati Respiratory Research 2013, 14(Suppl 1):S3
http://respiratory-research.com/content/14/S1/S3
Page 2 of 5
hypertension and then show a poorer outcome than those
without emphysema [22,23].
HRCT features consistent with a definite UIP pattern
may be asymmetrical in up to 25% of UIP cases. The
right lung is most frequently involved. Such a pattern
distribution of fibrosis is more common in UIP as com-
pared with other fibrotic ILD [24].
However, a definite UIP-like pattern may be also seen in
other disorders, such as fibrotic NSIP (especially when
associated with emphysema), connective tissue diseases,
chronic hypersensitivity pneumonitis, asbestosis, familial
ILD, sarcoidosis, vasculitis and Hermansky Pudlak syn-
drome [16,25-28]. In such cases, the recognition of addi-
tional ancillary findings (e.g. pleural plaques, centrilobular
nodules etc.) may help refine the differential diagnosis
between an idiopathic and a known etiology-associated
form (Table 1) [29].
“Possible” and “inconsistent” HRCT patterns
It is very important to realize that approximately half of
cases with biopsy-proven UIP does not show a definite
HRCT pattern owing to either the absence of typical
findings (i.e. honeycombing) (Fig. 2), or the presence of
findings (e.g. predominant ground-glass opacity, consoli-
dation, nodules etc.) suggesting alternative diagnoses
(Fig. 3) [3,30,31]. Such atypical HRCT patterns of UIP are
very similar or identical to those of NSIP, although in clin-
ical practice, they are likely to be misdiagnosed as a wider
range of diseases (e.g. chronic hypersensitivity pneumoni-
tis and sarcoidosis) [31].
In these patients, the absence of a typical HRCT pattern
calls for surgical biopsy that reveals a diagnosis of UIP.
The reason these patients fail to show the classic HRCT
appearances of UIP is still unclear, although it thought
that these are forms of initial disease or the expression of
the coexistence of UIP and NSIP in different parts of the
lung [10].
Thereby, the latest ATS/ERS/JRS/ALAT guidelines
(2011) outlined the HRCT features that meet the criteria
for “definite UIP”, “possible UIP” and “inconsistent with
UIP” patterns (Fig.1, 2, 3). Such classification system
should be used and eventually combined with the histolo-
gic data to diagnose IPF [6].
Nevertheless, it has been shown that some HRCT
indexes may predict both IPF diagnosis and prognosis. It
seems that patients with IPF who have possible or incon-
sistent UIP by HRCT criteria have a shorter survival than
those who show definite HRCT findings [30]. It has also
been shown that amongst patients with a non definite
UIP pattern, a higher HRCT score of the reticular
abnormality and older age are predictive of a diagnosis of
IPF [32].
Role of follow-up HRCT
Serial HRCTs show increases in extent and fibrosis over
months or years [25,33,34]. In drug trial setting HRCT is
the main tool to assess in vivo the morphologic response
to treatment [5,7]. However, the regular use of HRCT fol-
low-up is still controversial in routine practice and not yet
not recommended in clinically stable patients. Follow-up
HRCT might be indicated in those patients presenting
with an unexpected clinical-functional decline (i,e. to rule
out acute exacerbations) or when there is a non definite
UIP pattern on HRCT that cannot be characterized by
lung biopsy.
Acute exacerbation should be suspected in patients
with extensive or rapidly progressive new ground-glass
opacity (but sometimes consolidation) occurring on a
background of pre-existing fibrotic change typical of
UIP/IPF HRCT [35,36]. In such cases, however.,HRCT
interpretation should be carefully corroborated by clinical
findings as acute exacerbations’ HRCT features may
overlap with those of other acute complications such as
pulmonary infection and oedema.
Summary
The role of HRCT imaging in the evaluation and diagnosis
of patients with suspected IPF is central. When assessed
by expert clinicians and radiologists, the presence of typi-
cal clinical features and definitive UIP findings on HRCT
images are sufficient to allow a confident diagnosis of IPF.
However, the spectrum of HRCT manifestations of UIP
seems to be wider than commonly appreciated. HRCT has
also been shown to have some prognostic value in predict-
ing mortality although. further evidence is required to
prove such a value in clinical practice. Routine HRCT
Table 1 Ancillary CT findings suggesting other diagnoses in patients with a predominat UIP-like pattern.
Atypical CT features Probable diagnosis
Centrilobular nodules
Air trapping
Relative sparing of bases
Hypersensitivity
Pneumonitis
Pleural effusion; pleural thickening; esophageal dilation Collagen Vascular disease
Pleural plaques Asbestosis
Multiple septal or bronchovascular nodules in addition to reticulation Fibrosing Sarcoid
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Figure 2 Biopsy-proved UIP with a possible UIP pattern at HRCT. The transverse HRCT image through the lower lobes shows patchy and
peripheral reticular opacities without obvious honeycombing.
Figure 3 Biopsy-proved UIP with an HRCT pattern inconsistent with UIP. There are some patchy ground-glass and peripheral reticular
opacities. which are more suggestive of nonspecific interstitial pneumonia (NSIP).
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follow-up is not currently recommended due to lack of
sufficient evidence.
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